Last updated: July 10, 2026
ecutive summary: Horizon Therapeutics, LLC v. Par Pharmaceuticals, Inc. (D.N.J., 1:18-cv-01224) is a pharmaceutical patent infringement case tied to Horizon’s U.S. NDA and Par’s Abbreviated New Drug Application (ANDA) activity. The docket reflects litigation over alleged infringement of Orange Book-listed patents, with the case posture and outcomes governed by the Hatch-Waxman framework (Orange Book trigger → ANDA submission → infringement claims and, typically, Paragraph IV theories).
Horizon Therapeutics LLC v Par Pharmaceuticals 1:18-cv-01224: what claims and patents are at issue?
Answer (featured snippet): The case is a Hatch-Waxman patent infringement action brought by Horizon Therapeutics against Par Pharmaceuticals over an ANDA-linked product that Horizon alleged infringes Orange Book patents associated with Horizon’s NDA.
What infringement theory does the case follow in Hatch-Waxman filings?
Under the standard Hatch-Waxman structure, the patentee generally pleads:
- Direct infringement of one or more listed patents by the proposed ANDA product
- Often induced and/or contributory infringement (method and product use depending on patent types)
- Patent invalidity and non-infringement defenses by the ANDA filer
- “Delaware” and “Orange Book” type causation using the ANDA submission date as the litigation anchor for infringement timing
What patent categories typically drive these disputes?
Although the docket number is known, a complete, patent-by-patent summary requires the actual docket entries and the complaint’s asserted patent list. A litigation summary that names the specific asserted patents and claims must be grounded in docket documents.
Because the provided input contains only the case caption and docket number, a precise claims-and-patents breakdown cannot be produced without reproducing the asserted patent numbers and relevant paragraph/claim text.
1:18-cv-01224 procedural timeline: what happened from filing to key milestones?
Answer (featured snippet): The matter proceeds on the typical ANDA-Hatch-Waxman schedule: complaint → answer and patent defenses → claim construction and pretrial proceedings → merits and any settlement/consent judgment events if reached.
What are the standard milestone categories in a case like this?
In these cases, the most decision-relevant docket milestones usually include:
- Initial scheduling order (trial date, discovery cutoffs, expert deadlines)
- Markman/claim construction schedule
- Validity/infringement” discovery and expert reports
- Motions (dismissal, summary judgment, Daubert, injunction-related relief depending on the procedural posture)
- Event-driven resolution (stipulations, partial settlements, consent judgments, or final judgment)
What is the risk to generics from the timeline?
In practice, the strongest exposure moments are:
- Infringement and validity rulings
- Claim construction that narrows claim scope
- Any entry of an injunction or a standstill requiring FDA exclusivity navigation
What does the case mean for Par Pharmaceuticals’ ANDA and launch timing?
Answer (featured snippet): The lawsuit targets the FDA ANDA-linked launch and seeks to block an infringing commercial introduction until patent expiry or a settlement allowing a launch date.
How court outcomes translate into FDA pathway timing
For Orange Book-driven Hatch-Waxman cases:
- If the patentee wins on infringement and the court enjoins, launch is blocked until patent expiry
- If a settlement is reached, parties often define a specific “skinny label” / launch date and carve-outs
- If patents are found invalid/non-infringed, the ANDA filer can launch sooner (subject to any remaining patents and exclusivities)
Key commercial levers embedded in settlements
When Horizon and a generic filer settle, agreements typically address:
- Design-around permitted scope
- Labeling restrictions (method-of-use vs. product claim workaround)
- Carve-outs for additional indications/dosage forms
- Damages or covenant-not-to-sue structure and any royalty components
A complete analysis that maps litigation posture to launch risk requires the settlement or dispositive outcome in the docket, which is not supplied.
How does the Paragraph IV framework apply to Horizon v. Par?
Answer (featured snippet): The suit is consistent with a Paragraph IV infringement action triggered by Par’s ANDA filing challenging Horizon’s Orange Book patents.
Typical defenses raised by the ANDA filer
Par’s typical Hatch-Waxman defenses include:
- Non-infringement of one or more asserted claims
- Invalidity for obviousness, anticipation, lack of enablement, written description, indefiniteness, or improper patent subject matter theories (depending on the claim type)
- Statutory defenses under 35 U.S.C. § 271(e)(2) structure
- Evidentiary challenges to expert reports
How courts evaluate infringement in ANDA cases
In ANDA litigations, infringement analysis usually:
- Compares the accused ANDA product with the patent claim elements
- Uses reference to proposed product specs, dissolution data, and sometimes manufacturing process
- Applies claim construction outcomes to the product profile
What is Horizon Therapeutics’ patent estate strength in this matter?
Answer (featured snippet): The case posture is built around Orange Book-listed patents tied to Horizon’s NDA, and the estate strength is judged on how many asserted patents survive procedural challenges and how claim construction impacts infringement and validity.
What “strength” looks like on the docket
A patent estate is stronger when:
- Multiple patents are asserted and the plaintiff survives summary judgment on key ones
- Claim construction findings broadly support infringement
- Validity motions fail and the case reaches trial verdicts
- The settlement reflects broad scope protections, indicating practical litigation leverage
A precise strength assessment cannot be completed without enumerating asserted patents and the resolution of each.
What Orange Book status would be relevant for 1:18-cv-01224?
Answer (featured snippet): The relevant Orange Book entries are the patents listed for Horizon’s NDA that Par challenged in its ANDA submission and that Horizon asserted in the infringement complaint.
What to extract for an Orange Book-driven litigation readout
To tie docket events to Orange Book timelines, a proper summary requires:
- Patent numbers and listed expiration dates
- Drug product and dosage form covered
- Any FDA exclusivities (3-year, 5-year, pediatric, orphan exclusivity)
- Additional exclusivity that could independently delay generic entry even if patents are cleared
No drug identity or Orange Book patent list is included in the prompt.
Is there any biosimilar or interchangeability angle here?
Answer (featured snippet): This caption aligns with a small-molecule-style Hatch-Waxman dispute structure rather than a Biologics License Application biosimilar case.
Why biosimilar pathways are unlikely from the caption alone
Biosimilar litigation typically references BLA, 42 U.S.C. § 262(k), and the plaintiff and defendant roles reflect biosimilar developers rather than the Orange Book/ANDA structure. The docket number alone does not override the Hatch-Waxman framing implied by “Par Pharmaceuticals” and the typical Orange Book action pattern in such disputes.
A definitive biosimilar/non-biosimilar conclusion still requires the drug identity and FDA pathway details, which are not provided.
What other litigation risk signals matter for investors in this case?
Answer (featured snippet): The investor-relevant risk signals are (1) whether injunction or damages were pursued and (2) whether settlement locked in a delayed launch date versus an early FDA approval.
How to treat unresolved vs. resolved litigation in an earnings model
- Unresolved cases: model worst-case delay tied to the longest asserted patent/remaining appellate timelines
- Resolved cases: model the settlement-defined launch date and any remaining “blocking” patents or exclusivity
Without the docket outcome, there is no basis to map a timing range to revenue exposure.
Key takeaways
- Horizon v. Par (D.N.J. 1:18-cv-01224) is a Hatch-Waxman patent infringement case that hinges on Orange Book-listed patents asserted against an ANDA-based competitive product.
- The practical question for launch and licensing is how the case resolved (verdict vs. settlement) and which patents survived dispositive motions.
- A data-complete litigation summary with asserted patent numbers, claim themes, claim construction outcomes, and final disposition cannot be produced from the information supplied (case caption and docket number only).
FAQs
- What is the typical remedy Horizon seeks in ANDA patent cases like Horizon v. Par?
- How does claim construction usually affect infringement outcomes in Paragraph IV litigations?
- What docket events most strongly predict whether settlement will occur in Hatch-Waxman cases?
- How do Orange Book patent expirations interact with FDA exclusivity in determining generic launch timing?
- What damages theories are commonly pursued when an ANDA filer launches “at risk” during litigation?
References
- U.S. District Court, District of New Jersey. Horizon Therapeutics, LLC v. Par Pharmaceuticals, Inc., Civ. No. 1:18-cv-01224.
